Rearranged during transfection (RET) is involved in the physiological development of some organ systems. Activating RET alterations via either gene fusions or point mutations are potent oncogenic drivers in non-small cell lung cancer, thyroid cancer, and in multiple diverse cancers. RET-altered cancers were initially treated with multikinase inhibitors (MKIs). The efficacy of MKIs was modest at the expense of notable toxicities from their off-target activity.
Xcess Biosciences Inc (XcessBio or Xbio) was founded in 2008 by scientists from academia and BioPharma industry with strong expertise in chemistry and biology. We are dedicated to develop high-quality products and deliver the best services for our customers.
Your orders will be processed within 24 hours if the requested items are available in stock. We do not ship out orders on Friday. Orders received on Friday will be shipped out in the morning of the following Monday.
We diligently develop high quality products and strive to earn your satisfaction. If for any reason you are not satisfied with your purchases, please follow our Return Policy for product return or exchange.
If you know of any technology, product, or service development opportunities in the fields related, we would be very interested in hearing from you. Please Contact Us.